



(Translation)

October 19, 2021

Name of Company: Shiseido Company, Limited  
Name of Representative: Masahiko Uotani  
President and CEO  
(Representative Director)  
(Code No. 4911; The First Section of the Tokyo Stock Exchange)  
Contact: Harumoto Kitagawa  
Vice President  
Investor Relations Department  
(Tel: +81 3 3572 5111)

### **On Filing for International Arbitration by RepliCel Based on Terminated Contract**

On October 18, 2021 (PDT), RepliCel Life Sciences Inc. (headquartered in Vancouver, Canada; CEO and President: Lee Buckler; “RepliCel”), a Canadian bio-venture company, announced on its website that it had filed for international arbitration in accordance with the International Centre for Dispute Resolution (ICDR) Rules against Shiseido Company, Limited (the “Company”) regarding the Company’s termination of the Collaboration and Technology Transfer Agreement regarding hair cell technology in 2016.

It is the Company’s policy to refrain from comments at this stage, except to say that the Company believes the allegations made by RepliCel lack merit and it will vigorously defend the action.

In the event that any matters requiring disclosure arise in the future, the Company will promptly announce such matters.

—End of News Release—